Announced Wed, 24 Jun · 08:57 IST
Shilpa Biologicals commissions new ADC GMP manufacturing facility
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.3%1-day move
₹584.90
prior close
₹585.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+1.0+0.5+1.1-2.3-1.7+2.6-2.4+2.6+1.9+8.9+3.2——
Up moveDown movePending
AI summary
Shilpa Medicare's material subsidiary, Shilpa Biologicals, has commissioned a new state-of-the-art Antibody Drug Conjugate (ADC) GMP manufacturing facility. ADCs are advanced targeted cancer therapies and represent a high-growth segment in biopharmaceuticals. The facility is built to global GMP standards, expanding Shilpa Biologicals' manufacturing capabilities and opening doors for contract development and manufacturing opportunities in oncology.
Likely market impact
Strengthens the subsidiary's position in the high-value ADC segment; positive for long-term revenue and capability diversification.